<< Back
Printer Friendly Version View printer-friendly version
LifeMap Sciences Announces Release of LifeMap Discovery® Version 1.6 with Tissue-Specific, Fully Annotated Summaries of Gene Expression

ALAMEDA, Calif., March 13, 2014 – LifeMap Sciences, Inc. announced today the release of LifeMap Discovery® version 1.6 (discovery.lifemapsc.com). LifeMap Discovery® is a state-of-the-art roadmap of embryonic development and stem cell biology. The product integrates embryonic development and stem cell biology, molecular, cellular, anatomical, and disease-related information, and provides data-mining capabilities and bioinformatics applications. As such, it is a unique and powerful tool for research and discovery in multiple disciplines, including stem cell biology, developmental biology, disease mechanisms and etiology.

LifeMap Discovery® is a key component in LifeMap’s integrated database suite, a discovery platform for biomedical and stem cell research, which also includes GeneCards®, the leading human gene database (www.genecards.org), and MalaCards, the human disease database (www.malacards.org).  LifeMap Sciences holds the exclusive worldwide license to market GeneCards® and MalaCards from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science.

Version 1.6 of LifeMap Discovery® includes the following new features:

  • Gene Expression and GeneAnalytics™:
    • New, comprehensive list of genes expressed in a variety of organs / tissues and their related anatomical compartments and in vivo and in vitro cells.
    • Improved GeneAnalytics™ matching score. GeneAnalytics™, the gene expression analysis tool, applies a novel algorithm to match gene sets to tissues and cells within LifeMap Discovery®. The improved matching score algorithm now factors in genes that are specific and enriched within each organ/tissue, cell type and developmental path.
    • High throughput experiments: Integrated new resources including tooth and blood data, RNA sequencing data from the Human Protein Atlas, and new microarray experiments for several organs and anatomical compartments.
  • In vivo development - updated development paths for:
    • Cornea and lens development
    • Early endoderm development
  • Stem cells differentiation and regenerative medicine:
    • New differentiation protocols to derive renal cells and keratinocytes
    • New in vitro cells including: dental pulp stem cells and pluripotent naïve cells
    • Disease iPSC modeling for: Huntington’s disease, Retinitis pigmentosa and Fanconi’s anemia
    • New and updated cell therapy applications

“Version 1.6 offers our users a comprehensive list of annotated genes that are expressed in a variety of organs, tissues, cell types and developmental paths, such as motor neuron and oligodendrocyte differentiation, to name a couple,” said Ronit Shtrichman, Ph.D., Vice President of Biology at LifeMap Sciences. “This powerful knowledge will aid research and discovery efforts in academia and industry.”
“We are very pleased to see the growing interest in GeneAnalytics from both academia and industry, and we will continue to improve its capabilities,” said Yaron Guan-Golan, Head of Marketing at LifeMap Sciences.

About LifeMap Sciences, Inc.
LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on its Integrated Biomedical Knowledgebase and discovery platform for biomedical research, which currently includes GeneCards®, the leading human gene database; LifeMap Discovery®, the database of embryonic development, stem cell research and regenerative medicine; and MalaCards, the human disease database. LifeMap’s products are used in many institutions including academia, research hospitals, patent offices, and leading biotechnology and pharmaceutical companies. In addition to its currently marketed products, LifeMap is pursuing several new internet and informatics products with substantial rapid revenue growth potential, leveraging its existing products and their large user base.

LifeMap Sciences, Inc.

Kenneth Elsner, 781-826-7719
CFO and General Counsel